2026-07-282026-07-272026-07-242026-07-232026-07-222026-07-212026-07-202026-07-172026-07-162026-07-152026-07-142026-07-102026-06-292026-06-192026-06-182026-06-172026-06-162026-06-152026-06-122026-06-112026-06-102026-06-092026-06-082026-06-052026-06-042026-06-032026-06-022026-06-012026-05-302026-05-292026-05-282026-05-272026-05-252026-05-222026-05-212026-05-202026-05-192026-05-182026-05-152026-05-11
Stock-market dispatch — 2026-06-18
Auto-generated by the daily research routine (headless Pi run). Summary of what changed in the wiki today; the wiki is the truth. Research output, not advice — brain never trades.
Top of mind
Warsh's higher-for-longer FOMC is the day's central forcing function — it cascades through the whole financials/rate-regime book. Joseph Wang (former NY Fed trader) on Forward Guidance read the debut statement as a deliberate hawkish regime change ("the committee will deliver price stability, period… the entire curve basically shifted upward… more than one hike priced"). That one confirmation does three things: (1) opens a net-new chain — warsh-higher-for-longer-to-brokerage-nii-rerate: the market priced 2026 cuts into cash-sweep-heavy brokers (IBKR loses $108M NII per 25bp cut; BofA flagged cut-risk as the key overhang), so removing the cuts wrong-foots that haircut → SCHW/IBKR re-rate (IBKR +2.1% near its 52w high today). (2) Hardens p-and-c-insurer-float-income-rate-regime — the cut-path consensus assumes is now removed near-term. (3) DATES the amplifier on the #1 chain, ai-capex-derate-to-private-credit-contagion — the "growth-shock-with-inflation" scenario Ivascyn called "far worse for credit" is now the base case. The BDC dispersion is visible in price: short-leg FSK −5.2%/OWL −3.6%/OBDC −2.4% sit at/near 52w lows while long-leg ARCC/BXSL fell less — and Thoma Bravo's Medallia handover ($5.1B wiped; FSK marks it 79c vs Apollo 74c on the same loan) is the concrete mark-dispersion tell. Separately: MU reports Jun 24 (the book's nearest hard catalyst), and the paper ledger's first clean read that conviction labels are calibrated (high/med-high beat medium/low on sector-excess).
Strongest-conviction buys
Ranked shortlist from step 4c — chains, not advice. Prices 2026-06-18 (twelvedata, 63/64; THS 403'd carries prior).
| # | Ticker | Causal chain (mechanism) | Conviction | Valuation vs base | Fundamentals (one line) | Next catalyst |
|---|---|---|---|---|---|---|
| 1 | LIN | ras-laffan-halt-to-lin-helium-pricing-power | High (0.78) | At base — $515.85, ~2% off 52w hi; held flat in the chop | Net-cash industrial gas, 85–90% contracted; helium triple-sourced | APD Q3 late-July; Ras Laffan restart (un-dated) |
| 2 | MU | hbm-cowos-as-binding-bottleneck + helium-cliff-to-hbm-supply-crunch | Medium-high (0.68) | De-risked — $1,043.19 +2.2%, −6% from hi | HBM sold out several qtrs; GM ~81% Q3 guide; ~11× fwd; ledger's best pick (+24.9% sector-excess) | Q3 FY2026 earnings Jun 24 (the book's nearest gate) |
| 3 | CCJ | kazatomprom-supply-cut-to-western-uranium-premium + ai-capex-to-power-and-materials-cascade | Medium-high (0.72) | Yes — $105.67 −2.0%, −22% from hi; CCJ −9.6% vs URA −13.3% (selection +3.7%) | Term U $90 (14-yr high), ~1B lbs uncovered | Utility contracting; FERC Jun 30 (indirect) |
| 4 | WST | glp1-injectable-supply-chain-bottleneck | Medium-high (0.66) | Marginal — $323.59 −1.8% | GLP-1 ~18% of sales; per-unit consumable, price-agnostic — list-cut sharpens the consumable-over-manufacturer split | 503B comment-close Jun 29; Medicare $50 demo Jul 1 |
| 5 | TSM | hbm-cowos-as-binding-bottleneck | Medium-high (0.62) | Marginal — $432.15 +1.5%, near hi | CoWoS/HBM binding bottleneck; 50%+ GM, backlog | CoWoS adds; HBM4 ramp |
Watchlist
| Ticker | Thesis | Conviction | Price | Undervalued vs base? | Next catalyst |
|---|---|---|---|---|---|
| LIN | ras-laffan-halt-to-lin-helium-pricing-power | High | $515.85 | At base | APD Q3 late-July |
| MU | hbm-cowos-as-binding-bottleneck | Medium-high | $1,043.19 ↑2% | De-risked into print | Q3 earnings Jun 24 |
| CCJ | kazatomprom-supply-cut-to-western-uranium-premium | Medium-high | $105.67 | Yes | Contracting; FERC Jun 30 |
| WST | glp1-injectable-supply-chain-bottleneck | Medium-high | $323.59 | Marginal | 503B Jun 29; Medicare Jul 1 |
| TSM | hbm-cowos-as-binding-bottleneck | Medium-high | $432.15 ↑1% | Marginal | CoWoS/HBM4 |
| CEG | pjm-capacity-prices-to-nuclear-premium | Medium | $267.17 | Dislocated (−35% from hi) | FERC RM26-4 by Jun 30 |
| CF | hormuz-nitrogen-supply-shock-to-cf-risk-premium | Medium (premium fading) | $105.85 | H2 timed | H2 nitrogen season |
| MP | drone-warfare-demand-to-mp-hree-rerate | Medium | $60.84 ↑6.6% | Yes (−39% from hi) | HREE circuit H2'26 |
| NOW | agentic-ai-seat-erosion-to-saas-rerate | Medium (winner-long) | $95.48 ↓6% | Yes (−55% from hi) | Q2 FY2026 earnings |
| SCHW/IBKR | warsh-higher-for-longer-to-brokerage-nii-rerate | Low-med (hypothesis) | $94.51 / $95.09 | NII overhang removed | Q2 earnings; SCHW deposit trend |
| SPCX/RKLB/ASTS | spacex-ipo-comp-anchor-to-space-peer-fade | Low-med (active) | $191.82 / $107.98 / $85.43 | Convergence via SPCX-down | Lockup unlock ~late-Jun/early-Jul |
Undervalued candidates (today)
- CCJ $105.67 — term U $90 (14-yr high), −22% from hi; selection still positive vs URA.
- CEG $267.17 — −35% from hi; FERC RM26-4 order due by Jun 30.
- MP $60.84 (+6.6%) — −39% from hi; REE complex the day's relative-strength leg (USAR +8.3%).
New chains to investigate (hypothesis-stage)
- warsh-higher-for-longer-to-brokerage-nii-rerate — NEW (SCHW/IBKR). Warsh removes the consensus 2026-cut NII haircut priced into cash-sweep brokers → re-rate. Graduate on a sell-side NII model that still embeds cuts + SCHW deposit stabilization. → /explore-chain.
- ai-capex-derate-to-private-credit-contagion — hardened: forcing function now dated (Warsh), dispersion in price (short-leg BDCs at 52w lows), Medallia mark-dispersion concrete. Still #1 /explore-chain candidate.
- biosecure-act-domestic-cdmo-reshoring — updated (Samsung Bio top-3, Novo/Catalent consolidation), but no clean US-listed pure-play → stays low.
- Carryover: consumer-trade-down-to-private-label-manufacturer-treehouse (THS), el-nino-drought-to-water-infrastructure-capex (XYL/AWK), humanoid-actuator-magnet-demand-to-us-ree-stack (USAR/MP), talen-energy-replacement-cost-pjm-scarcity (TLN $409.81 +0.8%), mgm-diller-bid-floor-japan-dubai (MGM $46.94 −2%).
New theses (now active)
- None promoted to active concept. The day's net-new chain (brokerage-NII) and the hardened private-credit pair are
status: hypothesis— held pending /explore-chain.
Updated theses (existing active)
- p-and-c-insurer-float-income-rate-regime — Warsh confirms higher-for-longer (cut-path consensus removed near-term); tailwind hardens.
- ai-capex-derate-to-private-credit-contagion — amplifier dated + redemption-gate transmission (BCRED $3.8B/North Haven gated) + Medallia mark-dispersion. #1 /explore-chain.
- glp1-injectable-supply-chain-bottleneck — TrumpRx 74% list-cut + Medicare $50 Jul-1 → volume-over-price favors the consumable supplier (WST); new dollar-TAM falsifier added.
- spacex-ipo-comp-anchor-to-space-peer-fade — SPCX −9.3% while peers rallied (RKLB +3.2%/ASTS +3.9%): convergence now via SPCX deflating toward peers, not peer-fade. Lockup unlock the test.
Contradicted / weakened
- None. Today's ingest strengthens the rate-regime book rather than contradicting it. (KLAC paper-ledger mark is a data anomaly — suspected split — not a thesis contradiction; excluded from scoring.)
Open questions worth a human's eye
- MU Jun 24: does the sold-out HBM + ~81% GM guide print clean, or is DRAM inventory build the tell? The book's nearest hard catalyst.
- Private credit: does the BDC dispersion persist/widen (short-leg software marks deteriorate), or mean-revert because OBDC's marks are actually credible (asset sales at 99.7% of carry)?
- Brokerage NII: does consensus still embed a 2026-cut haircut for SCHW/IBKR, or is the re-rate already in the YTD run?
- SpaceX: does the $2.64T scarcity mark hold through the lockup/float-unlock, or keep deflating toward the peers?
What I looked at
- Run status: full headless Pi daily run (steps 0.5–7) completed synchronously; paced 63/64 + 5-ETF price fetch ran to completion in-turn (0 rate errors).
- Macro buckets: #9 Financials/rate-regime, #8 Healthcare — both thin verticals per 2a (ai-infrastructure 50%, ⚠ over; saas-ai-disruption thinnest).
- Ingestion veins (0.5–0.7): podcast-ingest 1 transcript (Forward Guidance/Warsh-Fed; Bg2 failed — AssemblyAI 400 + grok 403, 6th consecutive; Dwarkesh/Machiavelli skipped off-scope); earnings-ingest 0 (no-op, MU reports Jun 24); feed-ingest 0 (nothing new on-topic).
- Step-1: 1 gap-fill autoresearch (private-credit BDC dispersion + Warsh — the day's highest-value pass). Step-2 buckets: 2 (financials, healthcare). prospect-chains: 1 auto-draft (brokerage-NII); wiki otherwise well-connected.
- Sources promoted: 4; ingested: 4 → new pages: 1 hypothesis (warsh-higher-for-longer-to-brokerage-nii-rerate) + 1 person (joseph-wang); mechanisms updated: 1 (glp1); extract-mechanisms 0 net-new.
- Valuation: 63/64 tickers (twelvedata, 0 rate errors); THS 403'd (carries prior).
- Paper ledger (4d): weekly mark DONE — 20 positions re-marked; per-instrument +2.3% sector-excess; conviction ordering holds (high/med-high > medium/low); KLAC excluded (data anomaly ~8.9×); 2 SpaceX armed→open (IPO listed 06-12; orbital-DC +19.2%). Live feedback (4e):
performance-2026-06-18(22 positions) — 0 flagged < −10% sector → no auto-calibrate. Calibrations: 0 (theses strengthened, not contradicted). Conviction buys ranked: 5. New hypothesis chains opened: 1. - Signal feed: full active/armed set, gated ≥0.4 — see step 7 (Supabase sync performed by the wrapper, not this run).